Current Therapy of Sickle Cell Disease

Overview

Journal Haematologica

Specialty Hematology

Date 2006 Jan 26

PMID 16434364

Citations 23

Authors

Zakari Y Aliyu

Ashaunta R Tumblin

Gregory J Kato

Affiliations

Soon will be listed here.

Citing Articles

Maximizing longevity: erythropoietin's impact on sickle cell anaemia survival rates.

Obeagu E Ann Med Surg (Lond). 2024; 86(3):1570-1574.

PMID: 38463100 PMC: 10923353. DOI: 10.1097/MS9.0000000000001763.

Iron stores in steady-state sickle cell disease children accessing care at a sickle cell disease clinic in Kumasi, Ghana: A cross-sectional study.

Amanor E, Kwarteng A, Larbi A, Fordjour F, Koranteng K, Sackey D Health Sci Rep. 2022; 5(6):e934.

PMID: 36439047 PMC: 9686355. DOI: 10.1002/hsr2.934.

Personalized Cancer Medicine in the Media: Sensationalism or Realistic Reporting?.

Hicks-Courant K, Shen J, Stroupe A, Cronin A, Bair E, Wing S J Pers Med. 2021; 11(8).

PMID: 34442385 PMC: 8399271. DOI: 10.3390/jpm11080741.

Calibration of T oximetry MRI for subjects with sickle cell disease.

Bush A, Vu C, Choi S, Borzage M, Miao X, Li W Magn Reson Med. 2021; 86(2):1019-1028.

PMID: 33719133 PMC: 8076101. DOI: 10.1002/mrm.28757.

Development of Zinc Chelating Resin Polymer Beads for the Removal of Cell-Free Hemoglobin.

Simms K, Rebholz E, Mayberry R, Basu S, Perlegas A, Guthold M Ann Biomed Eng. 2019; 47(6):1470-1478.

PMID: 30919138 PMC: 6506348. DOI: 10.1007/s10439-019-02249-6.

References

Castro O, Sandler S, Houston-Yu P, Rana S . Predicting the effect of transfusing only phenotype-matched RBCs to patients with sickle cell disease: theoretical and practical implications. Transfusion. 2002; 42(6):684-90. DOI: 10.1046/j.1537-2995.2002.00126.x. View

Hankins J, Ware R, Rogers Z, Wynn L, Lane P, Scott J . Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood. 2005; 106(7):2269-75. PMC: 1895275. DOI: 10.1182/Blood-2004-12-4973. View

Barbui T . The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both?. Semin Hematol. 2004; 41(2 Suppl 3):15-7. DOI: 10.1053/j.seminhematol.2004.02.006. View

Taher A . Iron overload in thalassemia and sickle cell disease. Semin Hematol. 2005; 42(2 Suppl 1):S5-9. DOI: 10.1053/j.seminhematol.2005.01.005. View

Kinney T, HELMS R, Obranski E, Ohene-Frempong K, Wang W, Daeschner C . Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood. 1999; 94(5):1550-4. View

CHARACHE S, Barton F, Moore R, Terrin M, Steinberg M, Dover G . Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Medicine (Baltimore). 1996; 75(6):300-26. DOI: 10.1097/00005792-199611000-00002. View

Lin E, Rodgers G, Gladwin M . Hemolytic anemia-associated pulmonary hypertension in sickle cell disease. Curr Hematol Rep. 2005; 4(2):117-25. View

Hord J, Byrd R, Stowe L, Windsor B, Smith-Whitley K . Streptococcus pneumoniae sepsis and meningitis during the penicillin prophylaxis era in children with sickle cell disease. J Pediatr Hematol Oncol. 2002; 24(6):470-2. DOI: 10.1097/00043426-200208000-00012. View

. American Academy of Pediatrics. Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine,.... Pediatrics. 2000; 106(2 Pt 1):362-6. DOI: 10.1542/peds.106.2.362. View

10.

Gaziev J, Lucarelli G . Stem cell transplantation and gene therapy for hemoglobinopathies. Curr Hematol Rep. 2005; 4(2):126-31. View

11.

Walford G, Loscalzo J . Nitric oxide in vascular biology. J Thromb Haemost. 2003; 1(10):2112-8. DOI: 10.1046/j.1538-7836.2003.00345.x. View

12.

Walters M . Sickle cell anemia and hematopoietic cell transplantation: When is a pound of cure worth more than an ounce of prevention?. Pediatr Transplant. 2004; 8 Suppl 5:33-8. DOI: 10.1111/j.1398-2265.2004.00188.x. View

13.

Wanko S, Telen M . Transfusion management in sickle cell disease. Hematol Oncol Clin North Am. 2005; 19(5):803-26, v-vi. DOI: 10.1016/j.hoc.2005.07.002. View

14.

Miller M, Zimmerman S, Schultz W, Ware R . Hydroxyurea therapy for pediatric patients with hemoglobin SC disease. J Pediatr Hematol Oncol. 2001; 23(5):306-8. DOI: 10.1097/00043426-200106000-00014. View

15.

Vichinsky E, Haberkern C, Neumayr L, Earles A, Black D, Koshy M . A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. The Preoperative Transfusion in Sickle Cell Disease Study Group. N Engl J Med. 1995; 333(4):206-13. DOI: 10.1056/NEJM199507273330402. View

16.

Vichinsky E, Luban N, Wright E, Olivieri N, Driscoll C, Pegelow C . Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial. Transfusion. 2001; 41(9):1086-92. DOI: 10.1046/j.1537-2995.2001.41091086.x. View

17.

DeBaun M . Hydroxyurea as secondary prevention for stroke in children with sickle cell anemia. J Pediatr. 2005; 147(4):560-1. DOI: 10.1016/j.jpeds.2005.03.045. View

18.

Morris C, Kato G, Poljakovic M, Wang X, Blackwelder W, Sachdev V . Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA. 2005; 294(1):81-90. PMC: 2065861. DOI: 10.1001/jama.294.1.81. View

19.

Rother R, Bell L, Hillmen P, Gladwin M . The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA. 2005; 293(13):1653-62. DOI: 10.1001/jama.293.13.1653. View

20.

Stuart M, Nagel R . Sickle-cell disease. Lancet. 2004; 364(9442):1343-60. DOI: 10.1016/S0140-6736(04)17192-4. View